Pancreatic Cancer Research

ResearcherMedical College of WisconsinActive in the last 2 years

Thomas B. McFall

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5284-6994; OpenAlex author ID A5066121818. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2024: 2 papers · 2025: none · 2026: 6 papers

Papers 8

  1. MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. Co-author DOI 10.1093/oncolo/oyag040↗
  2. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Last author DOI 10.1158/0008-5472.can-25-0018↗
  3. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-2630↗
  4. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-26-1181↗
  5. The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection. Co-author DOI 10.3390/cancers18203376↗
  6. Oncogenic KRAS-MAPK signaling sustains a CD73 dependent therapeutic vulnerability in pancreatic cancer Co-author DOI 10.64898/2026.10.20.760559↗
  7. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.028↗
  8. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Co-author DOI 10.1177/17588359241253113↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mandana Kamgar · 6 shared papers, 2024–2026 · strength 1.37
  2. Douglas B. Evans · 5 shared papers, 2024–2026 · strength 1.10
  3. Razelle Kurzrock · 5 shared papers, 2024–2026 · strength 1.01
  4. William Adrian Hall · 4 shared papers, 2024–2026 · strength 0.89
  5. Yongwoo David Seo · 3 shared papers, 2026 · strength 0.77
  6. Susan Tsai · 4 shared papers, 2024–2026 · strength 0.74
  7. Mohammed Aldakkak · 3 shared papers, 2026 · strength 0.68
  8. G. Aaron Hobbs · 3 shared papers, 2026 · strength 0.62
  9. Kathleen K. Christians · 3 shared papers, 2024–2026 · strength 0.54
  10. Sam Z. Thalji · 2 shared papers, 2026 · strength 0.48
  11. Rachel A. Burge · 2 shared papers, 2026 · strength 0.42
  12. Channing J. Der · 2 shared papers, 2026 · strength 0.42
  13. Christabelle Rajesh · 2 shared papers, 2026 · strength 0.41
  14. Nikki K. Lytle · 2 shared papers, 2026 · strength 0.41
  15. Daniel Dorbin · 2 shared papers, 2026 · strength 0.41
  16. Ben George · 2 shared papers, 2024–2026 · strength 0.38
  17. Beth E. Erickson · 2 shared papers, 2024–2026 · strength 0.38
  18. Kshitij S. Gaur · 1 shared paper, 2026 · strength 0.36
  19. Elizabeth Diane Auckley · 1 shared paper, 2026 · strength 0.27
  20. Kathleen E. DelGiorno · 1 shared paper, 2026 · strength 0.26
  21. Urvinder Kaur Sardarni · 1 shared paper, 2026 · strength 0.26
  22. Khadija Shahab Turabi · 1 shared paper, 2026 · strength 0.26
  23. Marina Pasca di Magliano · 1 shared paper, 2026 · strength 0.26
  24. Jennifer M. Bailey · 1 shared paper, 2026 · strength 0.26
  25. Lu Han · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.